{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:18:36Z","timestamp":1768072716470,"version":"3.49.0"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,2,15]]},"DOI":"10.2169\/internalmedicine.9812-22","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T22:13:16Z","timestamp":1658441596000},"page":"613-616","source":"Crossref","is-referenced-by-count":8,"title":["Successful Treatment of an Aggressive Adult T-cell Leukemia\/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy"],"prefix":"10.2169","volume":"62","author":[{"given":"Yuta","family":"Baba","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Sakai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kabasawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T- cell leukaemia-lymphoma: a report from the lymphoma study group (1984-87). Br J Haematol 79: 428-437, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ohtsuka E, Kikuchi H, Nasu M, Takita-Sonoda Y, Fujii H, Yokoyama S. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma 15: 303-310, 1994.","DOI":"10.3109\/10428199409049728"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol 30: 1635-1640, 2012.","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"4","unstructured":"4. Imaizumi Y, Iwanaga M, Nosaka K, et al. Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci 111: 4567-4580, 2020."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007.","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 169: 672-682, 2015.","DOI":"10.1111\/bjh.13338"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ishida T, Jo T, Takemoto S, et al. Follow-up of a randomized phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol 184: 479-483, 2019.","DOI":"10.1111\/bjh.15123"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Oka S, Ono K, Nohgawa M. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anticancer Drugs 31: 536-539, 2020.","DOI":"10.1097\/CAD.0000000000000895"},{"key":"9","unstructured":"9. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393: 229-240, 2019."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33: 288-298, 2022.","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol 37: 677-687, 2019.","DOI":"10.1200\/JCO.18.00501"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cook LB, Phillips AA. How I treat adult T-cell leukemia\/lymphoma. Blood 137: 459-470, 2021.","DOI":"10.1182\/blood.2019004045"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 10: 457-470, 1998.","DOI":"10.1006\/smim.1998.0156"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. McDonald PP, Cassatella MA, Bald A, et al. CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol 25: 2870-2876, 1995.","DOI":"10.1002\/eji.1830251024"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakashima M, Yamochi T, Watanabe M, et al. CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals. Clin Cancer Res 24: 5445-5457, 2018.","DOI":"10.1158\/1078-0432.CCR-18-0268"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 124: 2983-2986, 2014.","DOI":"10.1182\/blood-2014-07-584953"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Takeshita M, Akamatsu M, Ohshima K, et al. CD30 (Ki-1) expression in adult T-cell leukaemia\/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 26: 539-546, 1995.","DOI":"10.1111\/j.1365-2559.1995.tb00272.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/4\/62_9812-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T03:27:38Z","timestamp":1676690858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/4\/62_9812-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9812-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"9812-22"}}